Equivalence Approach in Design of Experiments for Robustness Evaluation: Applications in Vaccines Development With JMP(R) ( 2019-EU-30MP-102 )
Mar 14, 2019 2:18 PM
| Last Modified: Mar 19, 2019 11:06 AM
Level: Intermediate Job Function: Analyst / Scientist / Engineer Industry: Health Care Bernard Francq, Principal Statistician, GlaxoSmithKline Dan Lin, Expert Biostatistician, GlaxoSmithKline Waldemar Miller, Statistician, GlaxoSmithKline Réjane Rousseau, Senior Statistician, GlaxoSmithKline Sylvie Scolas, Statistician, GlaxoSmithKline Walter Hoyer, Senior Manager, Innovation and Automation, CMC Stats, GlaxoSmithKline
Current state-of-the-art vaccines development is based on the Quality by Design paradigm. In design of experiments (DOE), the design space is defined as a subspace of process parameter combinations “that have been demonstrated to provide assurance of quality.” (ICH guidance Q8) The robustness of a process is its property to stay within the specification limits (target ± Δ) after a change in experimental conditions. A “DOE for flatness” extends the classical equivalence test (two one-sided test) to the multidimensional case (continuous or categorical factors). We’ll discuss the use of the multi-t distribution, as the entire experimental domain is compared to a reference level (usually the center point). The design space is then the subspace where the predicted means are equivalent to the reference level (confidence intervals of mean contrasts lie within ± Δ). Our methodology will be illustrated with applications in CMC statistics and vaccines development. We will discuss the limitations of the multiple comparisons and the Simulator in Prediction Profiler in JMP. We will show how to modify the default predicted values and the Contour Profiler to obtain an interactive design space to better communicate with the scientists. A JSL script will be shown to automate this procedure.